Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program

Stephen P. Mulligan, Stephen Opat, Chan Y. Cheah, Bryone Kuss, Mark Hertzberg, Paula Marlton, Sarah Poplar, Andrea Puig, Marija McGeachie, Robert Weinkove, Constantine S. Tam

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
56 Downloads (Pure)

Abstract

Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase indicated for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The Named Patient Program in Australia and New Zealand (ANZ NPP) provided access to ibrutinib treatment to 1126 R/R CLL/SLL and 330 R/R MCL patients, prior to Pharmaceutical Benefits Scheme listing. This study aimed to assess the duration of treatment for the ANZ NPP patients, as an indicator of efficacy and tolerability of ibrutinib in the real world. Based on the NPP data, ibrutinib provided a median of 47 months clinical benefit for participants with CLL/SLL and 14 months clinical benefit for those with MCL; outcomes that are consistent with the clinical trial results and further support the well-established efficacy and safety profile of ibrutinib in the real world.

Original languageEnglish
Pages (from-to)312-318
Number of pages7
JournalLeukemia and Lymphoma
Volume64
Issue number2
DOIs
Publication statusPublished - Feb 2023

Keywords

  • chronic lymphocytic leukemia
  • Ibrutinib
  • mantle cell leukemia
  • real-world

Fingerprint

Dive into the research topics of 'Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program'. Together they form a unique fingerprint.

Cite this